Media Center
 Baltimore and Montgomery counties often get a lot of press when it comes to biotechnology, but Frederick County has just as much to offer in the industry, said J.P. Matan, director of leasing for Matan Inc.
Being at the five-day International Biotechnology Convention in Washington, which ended Thursday, was one way of spreading the word about approximately 75 biotech companies in the county, Matan said.
"It's an important event for us and Frederick in general to showcase all the vibrant biotech companies we have," Matan said. (READ MORE)
 Under the leadership of Governor Martin O'Malley, Maryland continues to emerge as a national leader in the life sciences and biotech. With a unique set of assets, including the most PhDs per capita, the number-one public schools in the country, some of the best universities and institutions, and a highly skilled workforce, Maryland is the ideal location to build companies and organizations that work to fuel, feed, and heal our people. (READ MORE)
 Matan Companies, developer of National Cancer Institute’s 332,000-SF Advanced Technology Research Facility at Riverside Research Park in Frederick, Maryland, delivered the shell building 29 days ahead of schedule to SAIC-Frederick, to begin the tenant fit-out construction. “This project was anything but your typical office building construction. The facility was largely designed from the inside out to accommodate the unique specifications required to become a truly state-of-to-art research and development laboratory and manufacturing facility,” said Karl Morris, Director of Development for Matan Companies. (READ MORE)
 Geospiza and Maryland-based SAIC-Frederick Inc., government contractor for the National Cancer Institute in Frederick, Maryland, are collaborating to adapt Geospiza’s software platform to a new generation of rapid, high-resolution gene sequencing technology to potentially accelerate cancer research and help develop new treatments. (READ MORE)
 SAIC-Frederick, Inc. and Fluidigm Corporation are collaborating to decode the entire genome of the Epstein-Barr virus (EBV), using technology that can speed up research on the genetic basis of cancer and other diseases. (READ MORE)
Governor Martin O’Malley continued his “Jobs Across Maryland Tour” today and visited the National Cancer Institute at Riverside Research Park, a 330,000-SF advanced technology research facility being constructed in Frederick County. The research park is supporting up to 350 workers during construction, and the new facility will add approximately 200 additional jobs when complete. (READ MORE)
Gov. O'Malley announced a new program called InvestMaryland on Tuesday, an administrative and legislative proposal designed to support the growth of the state's knowledge-based industries by stimulating investment in the Maryland Venture Fund. (READ MORE)
Matan Companies attended the 2010 BIO Convention in Chicago, proudly showcasing their development, Riverside Research Park. With a booth situated in the Maryland Pavilion, the park proudly promoted the new 330,000-SF National Cancer Institute’s Advanced Technology Research Facility and NCI’s Advanced Technology Partnerships Initiative to a wide array of individuals from across the world. The highlight of the three-day show came when JP Matan, Director of Leasing, attended a private breakfast with Maryland’s Governor O’Malley, followed by a tour of the Riverside Research Park booth display. (SEE PHOTOS)
Matan Companies and Morgan-Keller, Inc. hosted a “tilt-up” party celebrating the construction progress for the National Cancer Institute’s 332,000-SF Advanced Technology Research Facility at Riverside Research Park in Frederick, MD. The goal of this state-of-the-art laboratory facility, slated for delivery in early 2012, is to enable scientists to more rapidly develop a new generation of highly targeted treatments for cancer patients. (READ MORE)
 Celator Pharmaceuticals today announced that the National Cancer Institute’s (NCI) Nanotechnology Characterization Laboratory (NCL), operated by SAIC-Frederick (Frederick, MD), has agreed to conduct characterization studies to advance the development of the company’s nanoparticle drug-formulation technology. (READ MORE)
Partnership to Develop and Study Cancer Models of Key Tumorigenesis Pathway Involved in Drug Resistance
The National Cancer Institute and its operations and technical-support contractor, SAIC-Frederick, Inc., have entered into a research-and-development collaboration with Mayo Clinic to expand on recent research discoveries at Mayo, where researchers have demonstrated the importance of a key protein involved in pancreatic and lung cancer. (READ MORE)
Ground was broken in November for the much-anticipated, state-of-the-art NCI facility that will house the Advanced Technology Partnerships Initiative (ATPI) and is the beginning of a new era to expand drug and technology development. As part of the larger 177-acre Riverside Research Park, NCI’s 62-acre site will have expansion capacity for another 470,000 SF, reserved for life-science and advanced technology partner organizations.
(READ MORE)
SAIC-Frederick, Inc., a contractor to the National Cancer Institute, has entered into a three-way research collaboration with Sporian Microsystems Inc. of
Lafayette, CO and the Food and Drug Administration (FDA), centering on a hand-held device for HIV testing that could potentially be used to improve
screening in remote areas. (READ MORE)
Collaboration Will Focus on Potential New Therapies for Cancer and Autoimmune Disease
Amplimmune, Inc., has entered into a broad agreement with the National Cancer Institute (NCI) for further advancement of two Amplimmune product candidates into therapies for cancer and autoimmune disease.
Under the Cooperative Research and Development Agreement (CRADA), Amplimmune will collaborate on multiple projects with NCI and its contractor, SAIC-Frederick Inc., under the umbrella of the NCI’s Advanced Technology Partnerships Initiative (ATPI). The goal of ATPI is to accelerate the translation of cancer and AIDS research into clinical therapies, diagnostics, and treatments. NCI-Frederick’s prime contractor, SAIC-Frederick, is facilitating these partnerships for NCI. (READ MORE)
The Matan Companies has teamed up with Federal Capital Partners (FCP) to complete the financing for the development of the National Cancer Institute’s 330,000 SF Advanced Technology Research Facility (ATRF) at Riverside Research Park in Frederick, Maryland. The state-of-the art 200-million-dollar office and laboratory facility will commence construction immediately and is slated for delivery in mid 2011. As part of the larger 177-acre Riverside Research Park, the National Cancer Institute’s 62-acre campus will have expansion capacity for another 570,000 square feet, reserved for life-science and advanced technology partner organizations. (READ MORE)
|
